CN101880280B - 双环嘧啶酮以及其应用 - Google Patents

双环嘧啶酮以及其应用 Download PDF

Info

Publication number
CN101880280B
CN101880280B CN201010148170.6A CN201010148170A CN101880280B CN 101880280 B CN101880280 B CN 101880280B CN 201010148170 A CN201010148170 A CN 201010148170A CN 101880280 B CN101880280 B CN 101880280B
Authority
CN
China
Prior art keywords
hydroxy
oxo
pyrimidine
nmr
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201010148170.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN101880280A (zh
Inventor
埃里克·戴尔·琼斯
乔纳森·艾伦·维克多·科茨
戴维·伊恩·罗兹
约翰·约瑟夫·戴德曼
尼古拉斯·安德鲁·范德格拉夫
莉萨·简·温菲尔德
内尔纳·天通
威廉·伊萨
尼尔·乔依
凯瑟琳·麦克法兰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tali Digital Ltd
Shanghai Institute of Organic Chemistry of CAS
Original Assignee
Avexa Ltd
Shanghai Institute of Organic Chemistry of CAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2006907283A external-priority patent/AU2006907283A0/en
Application filed by Avexa Ltd, Shanghai Institute of Organic Chemistry of CAS filed Critical Avexa Ltd
Publication of CN101880280A publication Critical patent/CN101880280A/zh
Application granted granted Critical
Publication of CN101880280B publication Critical patent/CN101880280B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D275/00Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201010148170.6A 2006-12-22 2007-12-21 双环嘧啶酮以及其应用 Expired - Fee Related CN101880280B (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
AU2006907283 2006-12-22
AU2006907283A AU2006907283A0 (en) 2006-12-22 Bicyclic pyrimidinones and uses thereof
AU2007902479A AU2007902479A0 (en) 2007-05-09 Bicyclic pyrimidinones and uses thereof (2)
AU2007902479 2007-05-09
AU2007903401 2007-06-25
AU2007903401A AU2007903401A0 (en) 2007-06-25 Bicyclic pyrimidinodes and uses thereof (3)
AU2007904114A AU2007904114A0 (en) 2007-07-31 Bicyclic pyrimidinones and uses thereof (4)
AU2007904114 2007-07-31

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN200780051562.7A Division CN101627019B (zh) 2006-12-22 2007-12-21 双环嘧啶酮以及其应用

Publications (2)

Publication Number Publication Date
CN101880280A CN101880280A (zh) 2010-11-10
CN101880280B true CN101880280B (zh) 2014-07-16

Family

ID=39562030

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201010148170.6A Expired - Fee Related CN101880280B (zh) 2006-12-22 2007-12-21 双环嘧啶酮以及其应用

Country Status (15)

Country Link
US (3) US8143268B2 (https=)
EP (2) EP2114903B1 (https=)
JP (2) JP5208962B2 (https=)
KR (2) KR20090097194A (https=)
CN (1) CN101880280B (https=)
AR (2) AR064517A1 (https=)
AT (1) ATE496898T1 (https=)
AU (2) AU2007336703B9 (https=)
BR (2) BRPI0722411A2 (https=)
CA (1) CA2673183C (https=)
DE (1) DE602007012308D1 (https=)
DK (1) DK2114903T3 (https=)
MX (1) MX2009006764A (https=)
NZ (1) NZ577491A (https=)
WO (1) WO2008077188A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102143962B (zh) * 2008-07-02 2015-03-11 爱维艾珂瑟有限公司 具有抗病毒特性的化合物
EP2291377B1 (en) * 2008-07-02 2015-02-18 Avexa Limited Imidazopyrimidinones and uses thereof
JP5539978B2 (ja) * 2008-07-02 2014-07-02 アベキサ・リミテッド チアゾピリミジノンおよびその使用
CN102336751A (zh) * 2010-07-16 2012-02-01 爱维艾珂瑟有限公司 新型抗病毒剂
WO2015038655A1 (en) 2013-09-12 2015-03-19 Alios Biopharma, Inc. Aza-pyridone compounds and uses thereof
US10195202B2 (en) 2013-12-19 2019-02-05 Ptc Therapeutics, Inc. Methods for modulating the amount of RNA transcripts
WO2016145103A1 (en) 2015-03-11 2016-09-15 Alios Biopharma, Inc. Aza-pyridone compounds and uses thereof
US10668171B2 (en) 2015-05-30 2020-06-02 Ptc Therapeutics, Inc. Methods for modulating RNA splicing
EA201800367A1 (ru) 2015-12-10 2019-02-28 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Способы лечения болезни хантингтона
JP2019535789A (ja) 2016-11-28 2019-12-12 ピーティーシー セラピューティクス,インコーポレーテッド Rnaスプライシングを調節する方法
EP3634953B1 (en) 2017-06-05 2024-01-03 PTC Therapeutics, Inc. Compounds for treating huntington's disease
JP2020523365A (ja) 2017-06-14 2020-08-06 ピーティーシー セラピューティクス,インコーポレーテッド Rnaスプライシングを改変する方法
MX2019015580A (es) 2017-06-28 2020-07-28 Ptc Therapeutics Inc Metodos para tratar la enfermedad de huntington.
CN111182898B (zh) 2017-06-28 2024-04-16 Ptc医疗公司 用于治疗亨廷顿氏病的方法
EA202092001A1 (ru) 2018-03-27 2021-01-29 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Соединения для лечения болезни гентингтона
WO2020005877A1 (en) 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
EP3814360B8 (en) 2018-06-27 2024-11-06 PTC Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
HRP20240935T1 (hr) 2018-06-27 2024-11-22 Ptc Therapeutics, Inc. Heterociklični i heteroaril spojevi za liječenje huntingtonove bolesti
JP7649257B2 (ja) 2019-05-13 2025-03-19 ピーティーシー セラピューティクス, インコーポレイテッド ハンチントン病を処置するための化合物
IL293340A (en) 2019-12-02 2022-07-01 Storm Therapeutics Ltd Polyheterocyclic compounds as mettl3 inhibitors
US12070445B2 (en) * 2021-08-27 2024-08-27 Wisconsin Alumni Research Foundation System and assay for monitoring production/release of membrane-lytic toxins in bacteria and compounds for modulating same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE283853T1 (de) 2000-09-20 2004-12-15 Schering Corp Substituierte imidazole als duale histamine h1 und h3 agonisten oder antagonisten
EP2161258A3 (en) 2002-11-20 2010-04-07 Japan Tabacco Inc. 4-oxoquinoline compound and use thereof as hiv integrase inhibitor
EP1697343B1 (en) 2003-12-18 2009-07-01 Tibotec Pharmaceuticals Ltd. Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication
TW200526635A (en) 2003-12-22 2005-08-16 Shionogi & Co Hydroxypyrimidinone derivative having HIV integrase inhibitory activity
EP1802591B1 (en) 2004-10-12 2012-01-11 AstraZeneca AB Quinazoline derivatives
CN101146811B (zh) 2005-03-31 2012-01-11 P.安杰莱蒂分子生物学研究所 Hiv整合酶抑制剂
CA2622639C (en) * 2005-10-04 2012-01-03 Istituto Di Recerche Di Biologia Molecolare P. Angeletti S.P.A. Hiv integrase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
M. Tisler et al..An improved synthesis of dimethyl diacetoxyfumarate and its condensation with heterocyclic amines.《Organic Preparations and Procedures International》.1990,第22卷(第4期),532-534. *

Also Published As

Publication number Publication date
MX2009006764A (es) 2009-11-26
HK1131615A1 (en) 2010-01-29
JP5208962B2 (ja) 2013-06-12
NZ577491A (en) 2011-06-30
EP2114903B1 (en) 2011-01-26
EP2269992A1 (en) 2011-01-05
DE602007012308D1 (de) 2011-03-10
BRPI0720564A2 (pt) 2011-08-16
AR077043A2 (es) 2011-07-27
KR20100049698A (ko) 2010-05-12
AU2007336703A1 (en) 2008-07-03
WO2008077188A1 (en) 2008-07-03
EP2114903A4 (en) 2009-12-30
DK2114903T3 (da) 2011-04-18
AU2007336703B2 (en) 2012-04-12
AU2010201160A1 (en) 2010-04-15
KR20090097194A (ko) 2009-09-15
US20100168063A1 (en) 2010-07-01
US8207334B2 (en) 2012-06-26
AU2007336703B9 (en) 2014-03-27
BRPI0722411A2 (pt) 2012-06-05
JP2010222370A (ja) 2010-10-07
US20120232035A1 (en) 2012-09-13
CA2673183A1 (en) 2008-07-03
CA2673183C (en) 2014-06-10
US8143268B2 (en) 2012-03-27
AR064517A1 (es) 2009-04-08
US20110009366A1 (en) 2011-01-13
JP2010513322A (ja) 2010-04-30
US8859563B2 (en) 2014-10-14
EP2114903A1 (en) 2009-11-11
ATE496898T1 (de) 2011-02-15
CN101880280A (zh) 2010-11-10

Similar Documents

Publication Publication Date Title
CN101880280B (zh) 双环嘧啶酮以及其应用
CN102143962B (zh) 具有抗病毒特性的化合物
BRPI0719361A2 (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo, métodos para melhorar a qualidade do sono em um paciente mamífero, para tratar insônia em um paciente mamífero e para tratar ou controlar obesidade em um paciente mamífero
WO2003080581A1 (en) Phenanthridinones as parp inhibitors
WO2022022680A1 (zh) 含氮并环类衍生物抑制剂、其制备方法和应用
JP2003321472A (ja) Grk阻害剤
CN101627028A (zh) 作为食欲素受体拮抗剂的取代的二氮杂环庚烷化合物
JP2020531593A (ja) Mystファミリーのkat阻害剤として作用する縮合[1,2,4]チアジアジン誘導体
CN100577663C (zh) 稠合杂环型激酶抑制剂
JP2023544157A (ja) Hsd17b13阻害剤及びその使用
TW202513045A (zh) Parg抑制劑
CN101627019A (zh) 双环嘧啶酮以及其应用
ES2358550T3 (es) Pirimidinonas bicíclicas y sus usos.
HK1131615B (en) Bicyclic pyrimidinones and uses thereof
EP4673445A1 (en) Sting agonists containing benzylic alcohol and benzylic amine functional groups
WO2025223550A1 (zh) 吡啶或吡嗪并三环化合物及其药用组合物和应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140716

Termination date: 20151221

EXPY Termination of patent right or utility model